What is Interspond?
Founded in 2003 by industry pioneer Kathy S. Cox, Interspond operates as a specialized Trial Management Organization. The company provides a comprehensive suite of services designed to streamline the clinical research lifecycle, ranging from site identification and feasibility assessment to regulatory document management and financial reconciliation. By maintaining a hybrid model that includes both exclusive and non-exclusive site partnerships, Interspond offers a versatile solution for multi-therapeutic research needs.
The firm's core competency lies in its operational efficiency during the critical pre-study phase. By managing the administrative and financial burdens of site selection, contract negotiation, and budget management, Interspond allows sponsors to focus on the scientific integrity of their phase 2 through 4 clinical trials. Their recent expansion into specialized neurology, rheumatology, and ophthalmology networks further solidifies their market position as a high-authority intermediary in the clinical research sector.
How much funding has Interspond raised?
Interspond has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Interspond
PPP
Public-Private Partnership
What's next for Interspond?
With the support of this recent capital injection, Interspond is well-positioned to scale its operational infrastructure and expand its network of research sites. The company's strategic roadmap likely involves deepening its penetration into specialized therapeutic areas, where the demand for high-quality, rapid-enrollment sites remains acute. As the industry shifts toward more decentralized and technology-enabled trial models, Interspond's established expertise in site management provides a robust foundation for future growth.
The firm will likely focus on enhancing its proprietary site-selection algorithms and streamlining its financial processing capabilities to further differentiate its value proposition to global CROs. By maintaining its commitment to operational excellence and site-level support, Interspond is poised to remain a cornerstone of the clinical research supply chain, facilitating the next generation of medical breakthroughs through improved trial execution.
